Skip to main content

ORIGINAL RESEARCH article

Front. Neurol.
Sec. Neurocritical and Neurohospitalist Care
Volume 15 - 2024 | doi: 10.3389/fneur.2024.1371314

Association between statins used and 30-day mortality in patients with sepsisassociated encephalopathy: A retrospective cohort study

Provisionally accepted
Junwei Chen Junwei Chen Junde Chen Junde Chen Lihong Li Lihong Li *
  • Fujian Medical University, Fuzhou, Fujian Province, China

The final, formatted version of the article will be published soon.

    Aim: Sepsis-associated encephalopathy (SAE) is a common and serious complication of sepsis with poor prognosis. Statin was used in SAE patients, while its effects on these patients remain unknown. This study aims to investigate the impact of statins used on 30-day mortality of SAE patients.: In this retrospective cohort study, data of SAE patients were extracted from the Medical Information Mart for Intensive Care IV (MIMIC-Ⅳ). Statins contained atorvastatin, pravastatin, rosuvastatin, and simvastatin. The outcome was 30-day mortality of SAE patients started after the 24 hours of the first ICU admission and at the first time after hospitalization. Potential covariates (socio-demographic characteristics, vital signs, score indexes, laboratory parameters, comorbidities, and treatment intervention methods) were selected by univariate Cox proportion hazard analysis. Associations of statins use, statin types with 30-day mortality were explored by univariate and multivariate Cox proportion hazard models, with hazard ratios (HRs) and 95% confidence intervals (CIs). Associations were further explored in different ages, gender, sequential organ failure assessment (SOFA), simplified acute physiology score II (SAPS II), and the Systemic Inflammatory Response Syndrome (SIRS) population.Results: Totally, 2,729 SAE patients were included, and 786 (28.8%) were dead within 30 days. Statins use was associated with lower odds of 30-day mortality (HR=0.77, 95%CI: 0.66-0.90) in all SAE patients. Patients who took simvastatin treatments were related to lower odds of 30-day mortality (HR=0.58, 95%CI: 0.43-0.78). Rosuvastatin treatments had a higher 30-day mortality risk (HR=1.88, 95%CI: 1.29-2.75). Statins use was also associated with lower 30-day mortality among patients of different ages, gender, sequential organ failure assessment (SOFA), SAPS II, and SIRS.Patients who were treated with simvastatin were associated with lower odds of 30-day mortality in SAE patients. Caution should be paid to statin use of SAE patients, especially in patients treated with rosuvastatin or pravastatin.

    Keywords: Statins, sepsis-associated encephalopathy, 30-day mortality, Mimic, Retrospective cohort

    Received: 16 Jan 2024; Accepted: 10 Dec 2024.

    Copyright: © 2024 Chen, Chen and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Lihong Li, Fujian Medical University, Fuzhou, 350108, Fujian Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.